CU24686B1 - Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b - Google Patents
Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis bInfo
- Publication number
- CU24686B1 CU24686B1 CU2020000097A CU20200097A CU24686B1 CU 24686 B1 CU24686 B1 CU 24686B1 CU 2020000097 A CU2020000097 A CU 2020000097A CU 20200097 A CU20200097 A CU 20200097A CU 24686 B1 CU24686 B1 CU 24686B1
- Authority
- CU
- Cuba
- Prior art keywords
- hepatitis
- prevent
- composition
- rinovacination
- obtaining
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title 2
- 231100000283 hepatitis Toxicity 0.000 title 2
- 208000002672 hepatitis B Diseases 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 abstract 1
- 229920002125 Sokalan® Polymers 0.000 abstract 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 abstract 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
- B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
- B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/02—Membranes or pistons acting on the contents inside the container, e.g. follower pistons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente invención se refiere a una composición de vacuna contra la hepatitis B, caracterizada porque comprende un antígeno de superficie de la hepatitis B y/o un antígeno de nucleocápside de la hepatitis B, y un material a base de gel que comprende polímero de carboxivinilo. La invención se refiere además a un proceso para preparar dicha composición vacunal y a un sistema de rinovacunación para prevenir y tratar la hepatitis B como se muestra en la figura 1.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018107797 | 2018-06-05 | ||
PCT/JP2019/022136 WO2019235466A1 (ja) | 2018-06-05 | 2019-06-04 | B型肝炎ワクチン経鼻投与システム |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20200097A7 CU20200097A7 (es) | 2021-07-02 |
CU24686B1 true CU24686B1 (es) | 2023-11-07 |
Family
ID=68769323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2020000097A CU24686B1 (es) | 2018-06-05 | 2019-06-04 | Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b |
Country Status (15)
Country | Link |
---|---|
US (1) | US12070497B2 (es) |
EP (1) | EP3804752A4 (es) |
JP (1) | JPWO2019235466A1 (es) |
KR (1) | KR20210022009A (es) |
CN (1) | CN112368018A (es) |
AU (1) | AU2019283122A1 (es) |
BR (1) | BR112020022784A2 (es) |
CA (1) | CA3099430A1 (es) |
CU (1) | CU24686B1 (es) |
IL (1) | IL278415B2 (es) |
MX (1) | MX2020013240A (es) |
PH (1) | PH12020552075A1 (es) |
SG (1) | SG11202011004RA (es) |
TW (1) | TW202002950A (es) |
WO (1) | WO2019235466A1 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030180351A1 (en) | 1998-11-06 | 2003-09-25 | Reinhard Gluck | Pharmaceutically active composition and dispensing device |
DE19851282A1 (de) * | 1998-11-06 | 2000-05-11 | Schweiz Serum & Impfinst | Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten |
CU22871A1 (es) | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
CA2439111A1 (en) | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
WO2007012319A1 (de) | 2005-07-29 | 2007-02-01 | Sigma-Aldrich Production Gmbh | Ionisierungsadditive enthaltende lc/ms-blends |
CA2648553C (en) | 2006-04-21 | 2015-01-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation |
ES2588183T3 (es) | 2009-03-31 | 2016-10-31 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal |
WO2013145789A1 (ja) | 2012-03-30 | 2013-10-03 | 株式会社吉野工業所 | 定量シリンジ型噴出器 |
WO2015199129A1 (ja) | 2014-06-25 | 2015-12-30 | 東興薬品工業株式会社 | インフルエンザワクチン経鼻接種システム |
JP6322844B2 (ja) | 2014-06-25 | 2018-05-16 | 東興薬品工業株式会社 | 医療用シリンジに用いられる点鼻用噴霧ノズル |
RU2603729C2 (ru) | 2015-04-24 | 2016-11-27 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты) |
JP6558392B2 (ja) * | 2017-04-04 | 2019-08-14 | ニプロ株式会社 | シリンジ型噴出装置 |
-
2019
- 2019-06-04 US US15/734,148 patent/US12070497B2/en active Active
- 2019-06-04 TW TW108119325A patent/TW202002950A/zh unknown
- 2019-06-04 CN CN201980035576.2A patent/CN112368018A/zh active Pending
- 2019-06-04 CU CU2020000097A patent/CU24686B1/es unknown
- 2019-06-04 MX MX2020013240A patent/MX2020013240A/es unknown
- 2019-06-04 CA CA3099430A patent/CA3099430A1/en active Pending
- 2019-06-04 WO PCT/JP2019/022136 patent/WO2019235466A1/ja active Application Filing
- 2019-06-04 SG SG11202011004RA patent/SG11202011004RA/en unknown
- 2019-06-04 EP EP19816086.3A patent/EP3804752A4/en active Pending
- 2019-06-04 JP JP2020523114A patent/JPWO2019235466A1/ja active Pending
- 2019-06-04 KR KR1020207038093A patent/KR20210022009A/ko unknown
- 2019-06-04 IL IL278415A patent/IL278415B2/en unknown
- 2019-06-04 BR BR112020022784-6A patent/BR112020022784A2/pt unknown
- 2019-06-04 AU AU2019283122A patent/AU2019283122A1/en active Pending
-
2020
- 2020-12-03 PH PH12020552075A patent/PH12020552075A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210022009A (ko) | 2021-03-02 |
EP3804752A4 (en) | 2022-03-09 |
WO2019235466A1 (ja) | 2019-12-12 |
JPWO2019235466A1 (ja) | 2021-06-24 |
MX2020013240A (es) | 2021-05-12 |
US12070497B2 (en) | 2024-08-27 |
TW202002950A (zh) | 2020-01-16 |
SG11202011004RA (en) | 2020-12-30 |
BR112020022784A2 (pt) | 2021-02-02 |
US20210187101A1 (en) | 2021-06-24 |
IL278415A (es) | 2020-12-31 |
IL278415B2 (en) | 2023-10-01 |
EP3804752A1 (en) | 2021-04-14 |
IL278415B1 (en) | 2023-06-01 |
CN112368018A (zh) | 2021-02-12 |
CU20200097A7 (es) | 2021-07-02 |
PH12020552075A1 (en) | 2021-05-31 |
CA3099430A1 (en) | 2019-12-12 |
AU2019283122A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013930A2 (pt) | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus | |
AR102657A1 (es) | Composición para tratar telas | |
CL2018000827A1 (es) | Tetrahidro-1h-pirido[3, 4-b] indol fármacos antiestrogénicos | |
MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
BR112018004242A2 (pt) | composições de vacina que possuem estabilidade e imunogenicidade aumentadas | |
MX2020004542A (es) | Metodo para inactivar el virus del zika y para determinar la inactivacion total. | |
AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
AR105434A1 (es) | Proceso para preparar pridopidina | |
PH12019500624A1 (en) | Swine comprising modified cd163 and associated methods | |
MX2017010908A (es) | Vacuna bivalente contra el virus de gripe porcina. | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
ZA202204981B (en) | Synthetic chimeric poxviruses | |
BR112017006511A2 (pt) | método para produção de uma manta de espuma | |
MX2020004633A (es) | Metodo para inactivar el virus de zika y metodos relacionados. | |
PH12018501154A1 (en) | Attenuated infectious bronchitis virus | |
AU2017261705A1 (en) | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | |
CY1125031T1 (el) | Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης | |
BR112016015078A2 (pt) | método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica | |
AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante | |
MX2017015004A (es) | Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina. | |
CU24686B1 (es) | Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b | |
CL2020002876A1 (es) | Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) | |
UY36208A (es) | “bacterias modificadas para vacunas mejoradas contra la brucelosis”. |